By Fineline Cube 
Shanghai Pharmaceutical Holding Co., Ltd. (SHA: 601607, HKG: 2607) on Aug. 28, 2025 announced its interim financial performance for the first half of 2025.
Key Financial Highlights
| Metric | H1 2025 | YoY % Change |
|---|---|---|
| Revenue | RMB 141.59 bn | +1.56 % |
| Total Profit | RMB 6.82 bn | +41.45 % |
| Pharma Manufacturing Revenue | RMB 12.16 bn | –4.50 % |
| Pharma Service Revenue | RMB 129.433 bn | +2.17 % |
| Innovative Drugs Revenue | RMB 24.2 bn | +22.6 % |
Segment Performance
- Pharma Manufacturing – Slight decline driven by higher material costs and a shift toward higher‑margin specialty products.
- Pharma Service – Modest growth from expanded contract‑manufacturing contracts, particularly in the U.S. and EU markets.
- Innovative Drugs – Strongest performer, reflecting accelerated commercialization of new biologics and small‑molecule therapies.
Pipeline & R&D Momentum
- 56 new pipeline candidates now in the clinical development pipeline, including 44 innovative drugs in various trial phases.
- Accelerated construction of R&D technology platforms:
- Macromolecule early‑stage platform
- Small‑molecule peptide platform
- PROTAC platform
- Translational evaluation platform
Commercial & Strategic Initiatives
- Retail Network – Coverage across 25 Chinese provinces with a robust wholesale‑retail integration.
- Strategic Partnerships – Collaborations with leading domestic and global pharmaceutical manufacturers, expanding market reach and co‑development opportunities.
- New Retail Integration Strategy – Launched to deepen wholesale‑retail collaboration, leveraging the company’s supply‑chain efficiencies and on‑site retail presence.
Outlook
Shanghai Pharma remains on track to meet its 2025 guidance, with a focus on expanding its innovative‑drug portfolio, enhancing R&D platform capabilities, and driving new‑retail synergies to capture higher margins across its distribution network.-Fineline Info & Tech